The image processing software is used for MRI image enhancement and can reduce noise in images from non-contrast MRI exams.

Ezra, a healthcare artificial intelligence (AI) startup specializing in early cancer detection through full-body MRI screening, announced the US Food and Drug Administration (FDA) granted 510(k) clearance for its Ezra Flash AI model. 

This new FDA clearance builds on its previous 510(k) clearance recognized in 2023 and enables Ezra to provide its partner imaging facilities with this latest product update. Ezra Flash, a Class II medical device, allows Ezra to enhance the quality of imaging not only for neuro MRI images but also for the abdomen and pelvis, expanding its applicability across the entire body. 

“This FDA clearance marks another milestone in our journey towards making affordable and fast full-body MRIs a reality,” says Emi Gal, founder and CEO of Ezra, in a release. “Our goal is to launch a 15-minute, $500 full-body MRI scan in 2026, and this new FDA clearance is an important step in that direction.”

According to the company, advancements to Ezra Flash include:

  • Image Quality: The latest FDA clearance improves image quality by reducing noise within the image while maintaining diagnostic integrity.
  • Imaging for Radiologist Analysis: Ezra’s improved image quality allows for more precise analyses, boosting radiologists’ ability to provide clear and actionable insights to patients.
  • Regulatory Standards: As with Ezra’s previous clearance, this FDA approval reassures that Ezra Flash meets health and safety standards

“The FDA clearance of Ezra Flash represents a significant advancement in making AI-powered cancer screening more accessible,” says Daniel K. Sodickson, MD, PhD, chief scientific advisor at Ezra, in a release. “This technology enables faster, more accurate early cancer detection, ultimately giving patients and their doctors clearer insights for making informed healthcare decisions.”

Ezra is leveraging AI across all three key components of the cancer screening process: imaging, analysis, and reporting. Ezra Flash AI enables Ezra to enhance MRI image quality, Ezra AI assists radiologists when interpreting MRI images (FDA-cleared for prostate MRI images), and Ezra Reporter AI creates a translation of radiology reports that assist medical professionals in communicating screening results to Ezra members. About 6% of scanned Ezra members have identified potential cancer.

Ezra’s technology is available at 74 locations in 29 cities across the US.

Summary:

The FDA has granted 510(k) clearance for an AI-powered image processing software designed to enhance MRI image quality. This clearance builds on a previous approval and expands the software’s application to neuro, abdominal, and pelvic imaging. The technology improves image clarity by reducing noise in non-contrast MRI scans, aiding radiologists in analysis. The company aims to further develop AI-driven advancements in imaging, interpretation, and reporting to make full-body MRI screening faster and more accessible.

Key Takeaways:

  • FDA Expands AI MRI Clearance – Ezra Flash allows Ezra to enhance the quality of imaging not only for neuro MRI images but also for the abdomen and pelvis, expanding its applicability across the entire body. 
  • Improved Image Processing – The software enhances MRI images by reducing noise in non-contrast MRI scans.
  • Advancing AI in Cancer Screening – The company says it continues to integrate AI across imaging, interpretation, and reporting to improve early cancer detection and screening efficiency.

Photo caption: Ezra Flash

Photo credit: Ezra